Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN) News
Filter BHVN News Items
BHVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BHVN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BHVN News From Around the Web
Below are the latest news stories about BIOHAVEN LTD that investors may wish to consider to help them evaluate BHVN as an investment opportunity.
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBiohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 13, 2025, at 8:15 am (PT). |
Insider Buying: Biohaven Independent Director Bought US$1.0m Of SharesBiohaven Ltd. ( NYSE:BHVN ) shareholders (or potential shareholders) will be happy to see that the Independent... |
Company News for Jan 2, 2025Companies In The News Are: X, BHVN, SGMO, PFE, BLDR. |
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst ApprovalOn Monday, Biohaven Ltd. (NYSE:BHVN) revealed clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE) platform and its glutamate modulation and ion channel programs. Immunoglobulin G (IgG) is a protein that helps prevent infections and is the most common type of antibody in the body. Elevated IgG levels can be seen in chronic active infection or inflammation. Subcutaneously administered BHV-1300 achieved deep lowering of targeted IgG, with re |
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Biohaven Ltd. (NYSE:BHVN) stands against the other weight loss stocks. The Revolution in Obesity Treatment: Opportunities and Challenges of GLP-1 Medications Most people have at some […] |
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program UpdatesBiohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted the achievement of several clinical and regulatory milestones across its proprietary Molecular Degrader of Extracellular Proteins (MoDE™) platform as well as its glutamate modulation and ion channel programs. |
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual MeetingBiohaven Ltd. (NYSE: BHVN) announced today that it is presenting expanded safety data from BHV-7000 multiple-dose studies at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10, 2024, in Los Angeles, California. Additional poster presentations highlight BHV-7000 nonclinical data and unmet needs that persist for people living with epilepsy, including the negative impact of adverse effects associated with current ASMs. |
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal StudyOn Monday, Biohaven Ltd. (NYSE:BHVN) updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity. In the RESILIENT SMA study, taldefgrobep showed clinically meaningful improvements in motor function at all time points on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did not statistically separate on the primary outcome at 48 weeks compared to the placebo+standard of care (SOC) group. Also Read: Biohaven Stock Spikes After Drug Candida |
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and ObesityBiohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, provided an update today regarding the taldefgrobep alfa development programs in SMA and obesity. |
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business DevelopmentsBiohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a review of recent accomplishments and anticipated upcoming developments. |